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Acute hypoxaemic respiratory failure (AHRF) is a key manifestation of acute coronavirus disease (COVID-19), caused by severe acute respiratory distress syndrome due to SARS-CoV-2 infection. COVID-19-related AHRF ranges from a mild self-limiting condition to severe progressive hypoxaemia requiring mechanical ventilation, with or without radiological evidence of bilateral consolidation and diffuse ground-glass lesions[@bib1], fulfilling the Berlin acute respiratory distress syndrome (ARDS)[@bib2] criteria. The severity of hypoxaemia in COVID-19 is often disproportionate to the reduction in lung volumes[@bib3], which may be a consequence of the effects of SARS-CoV-2 on pulmonary vascular tone, inflammation and thrombosis[@bib4], [@bib5], [@bib6].

The aim of this study was to compare respiratory parameters and outcomes for COVID-19 patients with ARDS from other causes of similarly severity of hypoxaemia using aggregate data from the LUNG-SAFE study[@bib7]. We present the clinical characteristics, lung mechanics, gas exchange and outcomes of a cohort of critically ill COVID-19 patients with AHRF receiving invasive mechanical ventilation with partial pressure of oxygen/inspired oxygen concentration ratio (PaO~2~/FiO~2~ ratio) \<300 mm Hg during their first critical care admission in a format similar to the LUNG-SAFE study[@bib7]. We grouped (COVID-19 *vs* LUNG-SAFE) patients based on the severity of oxygenation alone based on the Berlin definition of ARDS[@bib2]. Chest radiogram characteristics were not considered in the inclusion criteria.

The study was a single-centre, retrospective, observational cohort study of adult patients admitted with confirmed COVID-19 AHRF to the Critical Care Department at Guy's and St Thomas' Hospital (GSTT) in London UK between 3^rd^ March and 22^nd^ May 2020. The study had institutional approval and with waiver of individual informed consent (reference number 10796).

Baseline patient data, clinical characteristics, lung mechanics, gas exchange and outcomes were obtained from clinical information systems (CareVue Rev.F.01, Philips, Eindhoven, The Netherlands; and other electronic patient records) using Microsoft SQL Server Management Studio v18.4 (location?). Actual or temperature corrected partial pressure of carbon dioxide (PaCO~2~), PaO~2~ and pH, were merged with contemporaneous ventilation parameters and measurements. We used the worst PaO~2~/FiO~2~ ratio on critical care admission day to categorize hypoxaemia into mild (PaO~2~/FiO~2~ ratio 200-300 mm Hg), moderate (PaO~2~/FiO~2~ ratio 100-200 mm Hg) and severe (PaO~2~/FiO~2~ ratio ≤100 mm Hg) as per the Berlin ARDS definition[@bib2]. There were no missing data. All analyses were conducted in R version 3.6.1 (<http://www.R-project.org>).

Amongst the 317 critical care admissions over the study period due to COVID-19, 213 patients met our inclusion criteria of AHRF receiving invasive mandatory mechanical ventilation with PaO~2~/FiO~2~ ratio \<300 mm Hg, during their first critical care admission. We excluded patients receiving non-invasive respiratory support (n=48) or extracorporeal membrane oxygenation (ECMO; n=51), or readmissions (n=9). The mean (95% CI) age of the cohort was 56 (54-57) yr, 72.8% (n=155) were male, 40.4% (n=86) had hypertension and 33.8% (n=72) had diabetes mellitus as comorbidities.

There were 23 (10.8%) patients with mild, 122 (57.3%) with moderate and 68 (31.9%) with severe ARDS, based on PaO~2~/FiO~2~ ratio categories. Mean tidal volumes were ∼ 7 mL kg^-1^ of predicted body weight (PBW) for all three severity categories, with similar total minute ventilation. Mean PEEP was 10 (95% CI, 9.6-10.4)cm H~2~O, which increased from 8 (95% CI, 7.4-9.1) cm H~2~O in mild disease to 11 (95% CI, 10.5-11.9) cm H~2~O in severe disease. Values of peak inspiratory pressure and driving pressure increased with disease severity, with peak inspiratory pressures of 21 (95% CI, 19.4-22.6) cm H~2~O in mild, 24 (95% CI, 23.6-25.1) cm H~2~O in moderate, and 28 (95% CI, 26.4-28.7) cm H~2~O in severe disease. Delta pressure was 13 (95% CI, 11.3-14.4) cm H~2~O in mild, 14.7 (95% CI, 14.2-15.3) cm H~2~O in moderate and 15.4 (95% CI, 14.6-16.3) cm H~2~O in severe disease.

The majority of patients in all categories of severity had a peak airway pressure \< 30 cm H~2~O and received tidal volumes \< 8 mL kg^-1^ PBW ([Figure 1](#fig1){ref-type="fig"} A). Compliance of the respiratory system decreased from 41.2 (95% CI, 34.7-47.8) mL cm H~2~O^-1^ in the mild group to 31.9 (95% CI, 28.4-35.4) mL cm H~2~O^-1^ in the severe group, and 24% of patients in the moderate or severe AHRF groups had compliance \>40 ml cm H~2~O^-1^ ([Figure 1](#fig1){ref-type="fig"}B). Overall, mean (95% CI) duration of mechanical ventilation was 15 (13.5 to 16.5) days, with longer duration of mechanical ventilation associated with more severe disease ([Figure 1](#fig1){ref-type="fig"}C). The critical care length of stay was longer in the moderate and severe categories compared to the mild category, but similar in the moderate and severe categories due to higher and earlier mortality in the severe category. ICU mortality was 9% in mild disease, 27.5% in moderate disease and 55.7% in severe disease, with significant differences among the three severity categories (p\<0.01 log-rank), ([Figure 1](#fig1){ref-type="fig"}D).Figure 1Distribution of ventilation parameters on day 1 by ARDS severity and outcome. Figure- 1A, Distribution of tidal volume *vs* peak airway pressure. Figure- 1B; Distribution of tidal volume and driving pressure. Black diagonal line represents a compliance cut-off of 40 mL cm H~2~O^-1^. Upper-left triangle represents the distribution of patients with compliance \< 40 mL cm H~2~O^-1^. Lower-right triangle represents the distribution of patients with compliance \> 40 mL cm H~2~O^-1^, [Figure 1](#fig1){ref-type="fig"}C: Mortality (right Y-axis) and duration of mechanical ventilation (MV) or Intensive care unit (ICU) length of stay (LOS) by disease severity. Data are shown as mean (95% CI) **Figure- 1D:** Probability of ICU survival by disease severity.Figure 1

Overall ICU mortality of 34.2% in our cohort was similar to the overall mortality reported in the LUNG-SAFE (35.3%)[@bib7] cohort and in the COVID-19 cohort receiving mechanical ventilation (35%)[@bib8]. Similar to the LUNG-SAFE cohort and the Berlin ARDS predictive validity analyses, there was a dose-response relationship between mortality and severity of hypoxaemia, albeit with lower mortality in the mild category.

These results illustrate that although the characteristics of the COVID-19 AHRF population largely overlap with the LUNG-SAFE cohort, the COVID-19 cohort had a greater predominance of moderate (57% *vs* 47%) and severe (31% *vs* 23%) and a lower proportion of patients with mild hypoxaemia (10.8% *vs* 30%) compared to the LUNG-SAFE cohort[@bib7]. Despite the greater severity of hypoxaemia compared to LUNG-SAFE, a greater proportion of patients with COVID-19 were ventilated within protective boundaries.

In conclusion, despite initial data showing high mortality in mechanically ventilated COVID-19 patients, our data show that with comparable degrees of hypoxaemia and lung mechanics to ARDS from other causes the mortality is similar to ARDS as is survival is high in mild disease. More detailed characterizations of patient phenotypes may help understand the factors associated with severity of hypoxaemia and lung parenchymal involvement.
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